1025 (1025) Fair Value & Analysis

Consumer Cyclical · Market cap HK$89.0M

1 1025 1025 · HK

PriceHK$0.2200

Fair ValueHK$0.0500

Upside-77.3%

Quality36/100

Evidence: Low Range HK$0.0300 – HK$0.0700

Fair value as of: Jul 2, 2026

From 1 valuation models · updated today

Share price −13.7% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$0.1825 – HK$0.3450 · fair‑value band HK$0.0300 – HK$0.0700 · the HK$0.2200 price screens above the HK$0.0500 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

1025 (1025) currently trades at HK$0.2200, while our model-based Fair Value estimate is HK$0.0500 — implying the stock looks roughly 77.3% overvalued today. We read business quality at 36/100 (below-average quality), in the Consumer Cyclical sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

Over the trailing twelve months, 1025 generated revenue of HK$40.5M at a net margin of -81.3%. Revenue declined 58.5% year over year. It earns a return on equity of -76.4%. Net debt stands at HK$15.0M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$40.5M

Revenue growth (YoY) -58.5%

Net margin -81.3%

Return on equity -76.4%

Free cash flow −HK$11.6M FY2025

Operating margin -106%

More key figures

EPS (TTM) HK$-0.3200

Net debt HK$15.0M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

1025 reported revenue of HK$64.0M in FY2025 versus HK$62.7M in FY2021, a compound +0.5%/yr. Reported net income was −HK$23.8M in FY2025.

Revenue +0.5%/yr

FY21 HK$62.7M

FY22 HK$80.0M

FY23 HK$71.7M

FY24 HK$54.3M

FY25 HK$64.0M

Net income

FY21 −HK$44.7M

FY22 −HK$25.1M

FY23 −HK$31.3M

FY24 −HK$24.4M

FY25 −HK$23.8M

Is 1025 fairly valued? → Check now

Similar stocks

6 more Apparel Manufacturing stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
H & M Hennes & Mauritz AB HMB	kr 165.70	kr 144.10	-13%
Ralph Lauren Corporation RL	$366.55	$365.78	-0%
Moncler S.p.A MONRY	$57.68	$55.30	-4%
Gildan Activewear Inc GIL	$52.09	$33.02	-37%
LPP SA LPP	21,880 PLN	18,197 PLN	-17%
Levi Strauss & Co LEVI	$23.37	$16.66	-29%

Explore undervalued stocks

More undervalued Consumer Cyclical stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 1025 (1025) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$0.0500 versus a price of HK$0.2200 — about −77% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 1025?

Our model-based fair value for 1025 is HK$0.0500 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$0.2200.

What is the quality score of 1025?

1025 has a Quality Score of 36/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 1025 (1025)?

1025 reported trailing-twelve-month revenue of about HK$40.5M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 1025?

The net profit margin of 1025 is about -81.3%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.